FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


AlixPartners Adds New MD to Healthcare and Life Sciences Group

November 21, 2019, 08:35 AM
Related: ALixPartners

AlixPartners, the global consulting firm, announced that life sciences expert Frank Scholz has joined as a managing director and one of the key leaders in the firm’s global Healthcare and Life Sciences practice, focusing on helping lead efforts in the pharmaceutical sector. He will be based in AlixPartners’ Chicago office. 

Frank brings more than 20 years of high-level industry experience and broad-based consulting experience to his new position, and has deep experience in generics and branded pharmaceuticals, product commercialization, research & development, supply chain operations, quality management, and international M&A.

He joins AlixPartners from Mallinckrodt Pharmaceuticals, the registered business name of Mallinckrodt PLC, where he spent over six years, and most recently was executive vice president and chief operations & digital innovation officer. His responsibilities included commercial and R&D oriented strategic alliances, digital innovation, information technology, merger integration, strategic programs, procurement, global quality, and global operations for branded products.

Earlier in his career, Frank spent 16 years at consulting firm McKinsey & Company, where he rose to the level of partner, served clients globally in the pharmaceutical and medical devices industries, as well as in select other industries, including high technology.

Frank holds a Ph.D. in economics and business management from Bielefeld University in Bielefeld, Germany; an MBA from the McDonough School of Business at Georgetown University in Washington, D.C.; and a master’s degree in economics from Leibniz University Hannover in Hannover, Germany.

“We are extremely pleased to welcome Frank to AlixPartners,” said Simon Freakley, CEO of AlixPartners. “Disruption is hitting healthcare and life sciences companies like never before, and Frank’s broad experience and deep knowledge will prove invaluable to clients looking to turn that disruption into advantage.”

Week's News

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.